PHAROS IBIO CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11,220 KRW | -5.40% |
|
-9.30% | -24.34% |
| Sales 2022 | 300M 216K 295K | Sales 2023 | - | Capitalization | 192B 138M 188M |
|---|---|---|---|---|---|
| Net income 2022 | -17.06B -12.27M -16.75M | Net income 2023 | -8.86B -6.37M -8.7M | EV / Sales 2022 * | - |
| Net cash position 2022 | 14.71B 10.58M 14.45M | Net cash position 2023 | 25.18B 18.11M 24.73M | EV / Sales 2023 | - |
| P/E ratio 2022 * |
-
| P/E ratio 2023 |
-20.3
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 56.65% |
More Fundamentals
* Assessed data
| 1 day | -5.40% | ||
| 1 week | -9.30% | ||
| Current month | -7.88% | ||
| 1 month | -13.69% | ||
| 3 months | -40.63% | ||
| 6 months | -15.32% | ||
| Current year | -24.34% |
1 week
11 210.00
12 650.00
1 month
11 210.0013 170.00
Current year
11 200.0021 250.00
1 year
8 570.0025 000.00
3 years
8 570.0025 000.00
5 years
8 570.0025 000.00
10 years
8 570.0025 000.00
| Managers | Title | Age | Since |
|---|---|---|---|
Jung-Hyuk Yoon
CEO | Chief Executive Officer | 60 | 16-04-18 |
Sung-Won Mun
DFI | Director of Finance/CFO | 48 | 17-12-31 |
Ky-Youb Nam
PSD | President | 52 | 16-04-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jung-Hyuk Yoon
CEO | Chief Executive Officer | 60 | 16-04-18 |
Hye-Jung Han
PSD | President | 57 | 20-02-29 |
Ky-Youb Nam
PSD | President | 52 | 16-04-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-25 | 11,130 | -0.80% | 78,300 |
| 24-06-24 | 11,220 | -5.40% | 118,662 |
| 24-06-21 | 11,860 | -1.66% | 66,596 |
| 24-06-20 | 12,060 | +0.33% | 104,248 |
| 24-06-19 | 12,020 | -3.84% | 114,237 |
End-of-day quote Korea S.E., June 23, 2024
More quotes
Pharos IBio Co Ltd is a Korea-based company principally engaged in the research and development of new drugs. The Company principally engaged in the research and development of new drugs such as treatments for rare and intractable diseases. The Company is engaged in the development of treatments for rare and intractable diseases such as relapse-refractory ovarian cancer, acute myeloid leukemia, triple-negative breast cancer, recurrent acute myeloid leukemia as well as others.
| 1st Jan change | Capi. | |
|---|---|---|
| -24.34% | 103M | |
| +16.45% | 122B | |
| +21.96% | 116B | |
| +25.21% | 27.03B | |
| -20.05% | 20.36B | |
| -16.28% | 15.91B | |
| -15.96% | 16.43B | |
| -44.35% | 15.6B | |
| +63.91% | 14.94B | |
| +2.52% | 13.59B |
- Stock Market
- Equities
- A388870 Stock
